Your browser doesn't support javascript.
loading
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre, Toby A; Hildyard, Catherine; Hamblin, Angela; Ali, Ayesha S; Houlton, Aimee; Hopkins, Louise; Royston, Daniel; Linton, Kim M; Pettitt, Andrew; Rule, Simon; Cwynarski, Kate; Barrington, Sally F; Warbey, Victoria; Wrench, David; Barrans, Sharon; Hirst, Caroline S; Panchal, Anesh; Roudier, Martine P; Harrington, Elizabeth A; Davies, Andrew; Collins, Graham P.
Affiliation
  • Eyre TA; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
  • Hildyard C; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
  • Hamblin A; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
  • Ali AS; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Houlton A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Hopkins L; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Royston D; Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Linton KM; Department of Medical Oncology, The Christie Hospital NHS Trust, Manchester, UK.
  • Pettitt A; Department of Haematology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
  • Rule S; Department of Haematology, University of Plymouth Medical School, Plymouth, UK.
  • Cwynarski K; Department of Haematology, University College London, London, UK.
  • Barrington SF; Clinical PET Centre, St Thomas' Hospital, London, UK.
  • Warbey V; Clinical PET Centre, St Thomas' Hospital, London, UK.
  • Wrench D; Department of Haematology, Guy's and St Thomas' Hospital, London, UK.
  • Barrans S; Haematological Malignancy Diagnostic Service, St James' University Hospital, Leeds, UK.
  • Hirst CS; Translational Medicine, AstraZeneca Oncology R&D I Research and Early Development, Cambridge, UK.
  • Panchal A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Roudier MP; Translational Medicine, AstraZeneca Oncology R&D I Research and Early Development, Cambridge, UK.
  • Harrington EA; Translational Medicine, AstraZeneca Oncology R&D I Research and Early Development, Cambridge, UK.
  • Davies A; Cancer Research UK Centre, Cancer Sciences Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
  • Collins GP; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
Hematol Oncol ; 37(4): 352-359, 2019 Oct.
Article in En | MEDLINE | ID: mdl-31385336
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Benzamides / Morpholines / Lymphoma, Large B-Cell, Diffuse / Salvage Therapy / Protein Kinase Inhibitors / Molecular Targeted Therapy / Mechanistic Target of Rapamycin Complex 1 / Mechanistic Target of Rapamycin Complex 2 / Neoplasm Proteins Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Benzamides / Morpholines / Lymphoma, Large B-Cell, Diffuse / Salvage Therapy / Protein Kinase Inhibitors / Molecular Targeted Therapy / Mechanistic Target of Rapamycin Complex 1 / Mechanistic Target of Rapamycin Complex 2 / Neoplasm Proteins Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article